- In May 2024, Gerresheimer AG expanded its production capacity for dual chamber prefilled syringes at its facility in Bünde, Germany, to meet the increasing demand for lyophilized biologics and combination therapies. This strategic move enables Gerresheimer to support pharmaceutical companies with advanced drug delivery solutions tailored to stability-sensitive formulations, reinforcing its position as a key provider of high-quality primary packaging systems in the global injectable drug market
- In March 2024, SCHOTT Pharma announced the launch of its next-generation syriQ BioPure® dual chamber prefillable syringes designed for biologics requiring reconstitution. These syringes aim to improve drug stability, minimize interaction with container surfaces, and offer better compatibility with automation lines. The development reflects SCHOTT’s focus on innovation and its response to the growing need for safe, reliable, and patient-friendly drug delivery systems
- In February 2024, Vetter Pharma, a global contract development and manufacturing organization (CDMO), revealed the completion of a major expansion at its Ravensburg site, increasing capacity for dual chamber syringe filling. This enhancement allows Vetter to accommodate growing client demand for complex injectable therapies, particularly in the biologics and biosimilar markets. The expansion demonstrates Vetter’s commitment to addressing rising global demand for sophisticated, ready-to-use injection systems
- In January 2024, Credence MedSystems received industry recognition for its Dual Chamber Companion® syringe platform, which facilitates the delivery of combination therapies requiring separation until administration. The system supports automatic mixing, ensuring safety and ease-of-use for self-administration. This recognition underscores Credence’s innovation in developing intuitive drug delivery platforms aligned with evolving pharmaceutical trends toward user-centric designs and combination formulations
- In December 2023, Nipro Corporation announced the advancement of its dual chamber syringe solutions optimized for emergency drug administration. These syringes enable rapid and accurate reconstitution, crucial for time-sensitive medications. The development responds to the increasing global demand for injectable systems that ensure rapid drug deployment and high stability, particularly in critical care and field-based medical scenarios
